Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...
Zilucoplan is a subcutaneous, self-administered, macrocyclic peptide inhibitor of complement component 5. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
In the version of this article initially published, the numbers in the 'R sym ' row in Table 1 are in the wrong columns. The error has been corrected in the HTML and ...
Credit: Shutterstock. Zilucoplan is a synthetic, macrocyclic peptide inhibitor of complement component 5. Positive topline results were announced from a phase 3 study evaluating the efficacy and ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results